Key result
Single-dose GalNAc-siAGT sustains blood pressure reduction for ~2 months alongside cardio- and renoprotection in mice.
Why the study?
Current therapeutic strategies for hypertension lack sustained efficacy and long-term stability, necessitating a humanized rodent model to support drug development for small interfering RNA medications.
Does a modified GalNAc-siAGT targeting human hepatic angiotensinogen reduce blood pressure and protect against cardiac and renal comorbidities in a humanized hypertensive mouse model?
Does a modified GalNAc-siAGT targeting human hepatic angiotensinogen reduce blood pressure and protect against cardiac and renal comorbidities in a humanized hypertensive mouse model?
Answers are grounded in this paper and cite their sources.
A novel adeno-associated virus-induced humanized hypertensive mouse model validated the sustained 2-month antihypertensive and organ-protective effects of a single subcutaneous dose of GalNAc-siAGT, alone or combined with valsartan.
BACKGROUND: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long-term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. METHODS: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno-associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail-cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension-associated comorbidities were examined through histological analysis and ELISA. A modified N-acetylgalactosamine-conjugated small interfering RNA targeting human hepatic AGT (GalNAc-siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. RESULTS: The dual adeno-associated virus-induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc-siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc-siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio- and renoprotective effects. Moreover, combining GalNAc-siAGT with the renin-angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. CONCLUSIONS: Our study validated the antihypertensive therapeutic effect of GalNAc-siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2026) studied Hypertension. GalNAc-conjugated small interfering RNA targeting human hepatic AGT (GalNAc-siAGT) vs. Valsartan or untreated control was evaluated on Blood pressure reduction and cardio-/renoprotective effects. A single subcutaneous injection of GalNAc-siAGT in humanized hypertensive mice sustained blood pressure reduction for 2 months with cardio- and renoprotective effects.
Synapse has enriched 10 related papers. Consider them for comparative context: